Highlights
A collection of news and information related to Novartis AG published by this site and its partners.
Displaying items 1-12 of 109
» View wsbt.com items only
1
2
3
4
5
6
7
8
9
10
•
Next >
-
Deals of the day -- mergers and acquisitions
ReutersMay 16 (Reuters) - The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Thursday: ** DDR Corp, owner of shopping centers where big-box retailers are located, said on Wednesday it had agreed to buy from Blackstone Group LP...Tags: Sweden, Drugs and Medicines, Sprint Nextel Corporation, Mergers, Acquisitions and Takeovers, Brazil
-
Novartis says has no intention of buying Actavis
ReutersZURICH, May 16 (Reuters) - Novartis has no plans to bid for U.S.-based generic drugmaker Actavis, which is the subject of intense takeover speculation, a spokesman for the Swiss drugmaker said on Thursday. "We have no intention to pursue them," spokesman...Tags: The Wall Street Journal
-
DEALTALK-Novartis' Vasella exit opens door to Roche stake sale
Reuters* Novartis' one-third stake in Roche built up under Vasella * Vasella exit, retirement of Roche chairman could thaw relations * Roche seen as most likely buyer for the stake * Could make offer in second half of this year - analyst By Caroline...Tags: Parties and Movements, Genentech Inc., Merck & Company Incorporated, Drugs and Medicines, Elections
-
SEC says new settlements end 'Golden Goose' insider trading case
Reuters* Jamil Bouchareb, Daniel Corbin settle civil cases * Tips said to be misappropriated from PR firm executive May 15 (Reuters) - The U.S. Securities and Exchange Commission on Wednesday said it has reached settlements with the last two defendants in an...Tags: Insider Trading, Lehman Brothers Holdings Inc., Electronic Arts Inc., Prisons, Punishment
-
Acciones europeas alcanzan máximo 5 años impulsadas por papeles suizos
ReutersPor Sudip Kar-Gupta LONDRES, 15 mayo (Reuters) - Las acciones europeas treparon el miércoles a nuevos máximos de cinco años, lideradas por los avances de papeles suizos tras un retroceso del franco suizo que debería continuar beneficiando a los... -
Swiss stocks push European shares to fresh peaks
ReutersLONDON, May 15 (Reuters) - European shares scaled fresh five-year highs on Wednesday, led by gains for several major Swiss stocks after a currency shift that should continue to buoy the country's exporters. The pan-European FTSEurofirst 300 index...Tags: Exports, Central Bank, Credit Ratings
-
Acciones europeas cierran en alza, alcanzan máximo 5 años
ReutersLONDRES (Reuters) - Las acciones europeas treparon el miércoles a nuevos máximos de cinco años, lideradas por los avances de papeles suizos tras un retroceso del franco suizo que debería continuar beneficiando a los exportadores de ese origen. El í... -
Swiss stocks lift European shares to fresh heights
Reuters* FTSEurofirst 300 closes up 0.7 pct at 1,245.66 points * Euro STOXX 50 rises 0.5 pct to 2,809.58 points * Fall in Swiss franc buoys Swiss stock market * Oil pricing probe hits energy companies' stocks By Sudip Kar-Gupta LONDON, May 15 (Reuters) -...Tags: Royal Dutch Shell Plc, Stock Market, Central Bank, Prices, Credit Ratings
-
U.S. urged to take tougher line on Indian trade practices
Reuters* India is largest beneficiary in U.S. trade benefit program * U.S. Congress has already begun look at Indian practices By Doug Palmer WASHINGTON, May 14 (Reuters) - A U.S. think tank on Tuesday recommended Congress suspend trade benefits for India, in...Tags: U.S. Congress, Patents, Copyrights and Trademarks, U.S. House of Representatives, National Government, Science and Technology
-
A taste for defensives sours prospects for European stocks
Reuters* Defensive stocks unusually leading Europe stock rally * Healthcare price/earnings ratios at five-year highs * Fund managers still favour defensives -BofA ML survey By Tricia Wright LONDON, May 14 (Reuters) - Defensive stocks such as healthcare...Tags: Mutual Funds, JPMorgan Chase & Co., Chemical Industry, Finance, AstraZeneca Plc
-
RPT-ANALYSIS-Drugmakers face more scrutiny of discordant U.S. prices
Reuters(Repeats to widen readership) By Deena Beasley LOS ANGELES, May 10 (Reuters) - The world's biggest drug makers have for years enjoyed rich premiums for their medicines in the U.S. market. Those days may be coming to an end. Companies like Pfizer Inc...Tags: Social Sciences, Health Insurance Cost, Lipitor (drug), Environmental Issues, Emerging Market
-
XxANALYSIS-Drugmakers face more scrutiny of discordant U.S. prices
ReutersBy Deena Beasley LOS ANGELES, May 10 (Reuters) - The world's biggest drug makers have for years enjoyed rich premiums for their medicines in the U.S. market. Those days may be coming to an end. Companies like Pfizer Inc and AstraZeneca have grown...Tags: Health Insurance Cost, Social Sciences, Environmental Issues, Lipitor (drug), Emerging Market
May 16, 2013
|Story| Reuters
May 16, 2013
|Story| Reuters
May 16, 2013
|Story| Reuters
May 15, 2013
|Story| Reuters
May 15, 2013
|Story| Reuters
May 15, 2013
|Story| Reuters
May 15, 2013
|Story| Reuters
May 15, 2013
|Story| Reuters
May 14, 2013
|Story| Reuters
May 14, 2013
|Story| Reuters
May 10, 2013
|Story| Reuters
May 10, 2013
|Story| Reuters
Original site for Novartis AG topic gallery.